[HTML][HTML] Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor
GM Lai, SL Yan, CS Chang, CY Tsai - World Journal of …, 2013 - ncbi.nlm.nih.gov
GM Lai, SL Yan, CS Chang, CY Tsai
World Journal of Gastroenterology: WJG, 2013•ncbi.nlm.nih.govHepatitis B virus (HBV) reactivation is a well-recognized complication in patients with
chronic HBV infection receiving cytotoxic or immunosuppressive chemotherapy. Imatinib
mesylate and nilotinib are selective Bcr/Abl tyrosine kinase inhibitors, which are now widely
used in the treatment of patients with chronic myeloid leukemia. Although HBV reactivation
induced by imatinib mesylate has been reported, nilotinib-related HBV reactivation has not
been reported in the English literature. We report here 2 cases of HBV reactivation in chronic …
chronic HBV infection receiving cytotoxic or immunosuppressive chemotherapy. Imatinib
mesylate and nilotinib are selective Bcr/Abl tyrosine kinase inhibitors, which are now widely
used in the treatment of patients with chronic myeloid leukemia. Although HBV reactivation
induced by imatinib mesylate has been reported, nilotinib-related HBV reactivation has not
been reported in the English literature. We report here 2 cases of HBV reactivation in chronic …
Abstract
Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with chronic HBV infection receiving cytotoxic or immunosuppressive chemotherapy. Imatinib mesylate and nilotinib are selective Bcr/Abl tyrosine kinase inhibitors, which are now widely used in the treatment of patients with chronic myeloid leukemia. Although HBV reactivation induced by imatinib mesylate has been reported, nilotinib-related HBV reactivation has not been reported in the English literature. We report here 2 cases of HBV reactivation in chronic myeloid leukemia patients receiving imatinib mesylate and a novel case of nilotinib related HBV reactivation.
ncbi.nlm.nih.gov